Hydroxyl-Terminated Polyethylene Glycol Evades Human Pre-existing Anti-polyethylene Glycol Antibodies
- 9 June 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Nano
Abstract
Polyethylene glycol (PEG) has been extensively utilized in food, cosmetics, and pharmaceutical fields, especially in the realm of nanomedicines, where it serves as a pivotal excipient to prolong the nanoparticles' circulation half-life. Contrary to its historical perception as being nonimmunogenic, pre-existing anti-PEG antibodies have been widely detected in human even in individuals without prior exposure to PEGylated therapeutics and are associated with clinically relevant adverse effects of PEGylated nanomedicines including infusion reactions and hypersensitive reactions. Herein, we elucidated the prevalence and distribution characteristics of pre-existing anti-PEG antibodies in 1970 human blood samples and investigated its binding with PEG. The binding between pre-existing anti-PEG IgM and PEG was modulated by PEG terminal chemistry, with methoxy groups enhancing overall antibody-PEG interactions. Notably, methoxy is the only terminal configuration used in currently marketed PEGylated nanomedicines. In contrast, hydroxy PEG (OH-PEG) significantly evaded binding with pre-existing anti-PEG IgM among most clinical samples from three independent hospitals. Noteworthily, replacing methoxy PEG (MeO-PEG) with OH-PEG significantly attenuated complement activation of lipid nanoparticle (LNP) caused by pre-existing anti-PEG IgM, thereby markedly enhancing stability and reducing mRNA leakage in human serum. Additionally, LNP modified with OH-PEG exhibited reduced immunogenicity, which is crucial for repeated administrations. Collectively, this study elucidated the crucial role of OH-PEG in evading human pre-existing anti-PEG antibodies and discovered that the current preclinical studies inadequately simulated the biological effects of clinical pre-existing anti-PEG antibodies on such formulations through interspecies study, which had a profound impact on clinical translation of PEGylated nanomedicines.Keywords
Funding Information
- The Research Grants Council of the Hong Kong Special Administrative Region (N_HKU778/23)
- The Innovation and Technology Commission of the Hong Kong Special Administrative Region (MHP/269/24)
This publication has 67 references indexed in Scilit:
- The role of lipid components in lipid nanoparticles for vaccines and gene therapyAdvanced Drug Delivery Reviews, 2022
- To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternativesAdvanced Drug Delivery Reviews, 2021
- Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative reviewClinical Microbiology and Infection, 2021
- PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM productionInternational Journal of Pharmaceutics, 2020
- Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease ActivityArthritis & Rheumatology, 2018
- A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2018
- PEGylation as a strategy for improving nanoparticle-based drug and gene deliveryAdvanced Drug Delivery Reviews, 2016
- Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effectsAdvanced Drug Delivery Reviews, 2011
- Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomesInternational Journal of Pharmaceutics, 2008
- Sequence and structural determinants of mannose recognitionProteins: Structure, Function, and Bioinformatics, 2000